![]() Its revenue surged 89 percent to CNY942 million. In 2020, LinkDoc widened its net loss by 12 percent to CNY489 million (USD75.4 million) from 2019 due to its high research and development, as well as labor costs. But founder and Chief Executive Zhang Tianze has 19.7 percent of the equity, resulting in the biggest stake. Alibaba currently is the fifth-largest shareholder with its 8.4 percent stake in the IPO-hopeful. Chi-Med Files New Prospectus for 100 Million US IPO Member Content. ![]() The latest one was in March, participated by the Hangzhou-based e-commerce giant. LinkDoc Raises 103 Million for Oncology AI/Big Data Services Member Content. The startup has completed five rounds of financing. It had set up 34 service centers in 28 provinces with more than 400,000 registered patients by March. Alibaba's affiliate would spend USD25 million.įounded in 2014, LinkDoc offers its diagnostics and treatment information services to cancer patients in China via its online and offline platforms. The group includes Lake Bleu Capital, Temasek Holdings, UBS Asset Management, Hudson Bay Capital, and Sage Capital. Six investors, including Alibaba Health Hong Kong Technology, have expressed their intentions to buy nearly half of the shares before the IPO, the prospectus added. Underwriters may subscribe to an additional 1.6 million ADSs under a greenshoe option. LinkDocs decision to suspend its 211 million IPO, first reported by Reuters, is likely to be followed by others, analysts said, although they noted that U.S. The oncology data platform will issue 10.8 million American depositary shares at a price range of USD17.50 to USD19.50, the Beijing-based firm said in its updated prospectus filed with the US Securities and Exchange Commission yesterday. (Yicai Global) July 2 - China's LinkDoc Technology, a medical data company invested by Alibaba Group Holding's healthcare arm, aims to raise up to USD243 million in its initial public offering on the Nasdaq.
0 Comments
Leave a Reply. |